MedTrace Logo

Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice

NCT04137120 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2023-02-17

No results posted yet for this study

Summary

The study aims to collect data on the safety and use of intravitreal aflibercept injections into the eye for the treatment of eye disorders that cause blurred vision or a blind spot due to abnormal or blocked blood vessels. Data will be collected from patients who are being treated for such eye disorders in Mexican routine clinical practice.

Conditions

  • Retinal Disease

Interventions

DRUG

Aflibercept (BAY86-5321, Eylea)

Intravitreal injection of aflibercept as scheduled by treating physician

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-19
Primary Completion
2022-08-17
Completion
2023-02-01

Countries

  • Mexico

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04137120 on ClinicalTrials.gov